Law Firms Urge Corcept Investors To Seek Lead Role In Securities Case Before April 21

Overview

• Multiple shareholder firms issued new notices reminding Corcept investors of the April 21, 2026 deadline to ask the court to be lead plaintiff in the securities class action.
• Plaintiffs say Corcept told the market relacorilant was approaching approval and called its trials powerful, even as the FDA had warned in pre‑submission meetings that the evidence was not adequate.
• The filed case, Allegheny County Employees’ Retirement System v. Corcept Therapeutics Inc., No. 26‑cv‑01525, is pending in the U.S. District Court for the Northern District of California.
• After Corcept later disclosed an FDA Complete Response Letter, which is a rejection that asks for more data before approval, the stock fell about 50% in a day and the complaint cites roughly $2.5 billion in lost value.
• The putative class covers purchases from October 31, 2024 through December 30, 2025, no class has been certified, and investors can choose their own counsel even if they do not seek the lead role.